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Comment
Ovarian Tissue Cryopreservation: A Window into the
Reproductive Justice Concerns Underlying Assisted
Reproductive Technologies
CAITLYN PESAVENTO
More regulatory framework is needed for assisted reproductive technologies.
Taken together, the high costs of fertility treatment, lack of widespread insurance
coverage, and social perceptions of motherhood make it nearly impossible for
women from traditionally marginalized backgrounds to collectively overcome
barriers of access to fertility treatments. Viewing the ovarian tissue cryopreservation
procedure through a reproductive justice framework illustrates an inherent dichotomy
between increasing availability and increasing access to assisted reproductive
technologies. This Comment explores the current regulation—or lack thereof—of
assisted reproductive technologies; advocates for the regulation of ovarian tissue
cryopreservation by the U.S. Food and Drug Administration; scrutinizes the failings
of the insurance industry’s coverage of infertility treatments; and exposes a common
ideology that a woman’s social worth is intimately linked to her reproductive
capabilities and destined motherhood.
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Ovarian Tissue Cryopreservation: A Window into the
Reproductive Justice Concerns Underlying Assisted
Reproductive Technologies
CAITLYN PESAVENTO *
INTRODUCTION
Ovarian tissue cryopreservation (OTC) is now one of many assisted
reproductive technology (ART) treatments available to combat infertility.
OTC can efficiently preserve hundreds of primordial ovarian follicles in one
retrieval process.1 This technique has primarily been used to safeguard
fertility in cancer patients undergoing gonadotoxic treatments and may also
be useful for patients with conditions such as recurrent ovarian cysts, ovarian
torsions, endocrine disorders, and autoimmune diseases.2 The American
Society for Reproductive Medicine’s (ASRM) recent removal of OTC’s
experimental label will likely give more women the ability to treat infertility,3
but it will not increase the number of women who can access fertility treatments.
An inherent dichotomy exists within the scientific advancements of
ARTs. On the one hand, emerging ARTs should be celebrated for their
fertility treatment capacities. Yet, on the other hand, new technologies alone
will not solve reproductive justice issues that lie in the shadows of
reproductive regulation and its insurance coverage—or lack thereof.
Looking at OTC as a case study for the intersection of these tensions

*
University of Connecticut School of Law, J.D. Candidate, 2022; University of Connecticut, B.A.,
2020, B.S., 2020. Thank you to my sister, Danielle, for inspiring my advocacy; my parents, Antoinette
and Bruno, for their love and support; Austin Carfi for always championing me and my ambitions; my
colleagues at the Connecticut Law Review for their editorial efforts; and Professor Richard Michael Fischl
for his unwavering belief in me.
1
Sanghoon Lee, Sinan Ozkavukcu & Seung-Yup Ku, Current and Future Perspectives for
Improving Ovarian Tissue Cryopreservation and Transplantation Outcomes for Cancer Patients, 28
REPROD. SCI. 1746, 1747 (2021).
2
Ellen Cristina Rivas Leonel, Carolina M. Lucci & Christiani A. Amorim, Cryopreservation of
Human Ovarian Tissue: A Review, 46 TRANSFUSION MED. & HEMOTHERAPY 173, 174 (2019).
Gonadotoxic treatments are those that damage the reproductive system through the destruction of sperm
and eggs. Fertility Risks from Treatment, A LL. FOR FERTILITY PRES., https://www.allianceforfertilitypr
eservation.org/fertility-risks-from-treatment (last visited Nov. 2, 2021).
3
The ASRM published its removal of the experimental label in March of 2020. Erin E. Rowell,
Francesca E. Duncan & Monica M. Laronda, ASRM Removes the Experimental Label from Ovarian
Tissue Cryopreservation (OTC): Pediatric Research Must Continue, AM. SOC’Y FOR REPROD. MED.:
FERTILITY & STERILITY (Mar. 26, 2020), https://www.fertstertdialog.com/posts/asrm-removes-theexperimental-label-from-ovarian-tissue-cryopreservation-otc-pediatric-research-must-continue.
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illustrates how abstract concepts, such as motherhood, reproductive justice,
and socioeconomic status, impact ART procedures for women. 4
This Comment explores the current regulation of ARTs and the potential
regulation of ovarian tissue procedures, the lack of access to ARTs from an
insurance coverage perspective, concerns for the nonmedically necessary
use of OTC, and the intersection of social identity and reproduction.
I. FEDERAL REGULATION OF REPRODUCTIVE CRYOPRESERVATION
There is no comprehensive federal law relating to ARTs,5 and state
regulation of private fertility clinics and gamete banks is lacking.6 OTC
should—and likely will—be regulated alongside tissue transplants under the
Food and Drug Administration (FDA), rather than with organ transplants
under the U.S. Department of Health and Human Services (HHS). When the
FDA promulgated regulations for cell and tissue donations, it included gamete
donations as one type of covered cell.7 Despite this, extensive regulation of
reproductive cell and tissue transplants still falls short.8 As a result, state and
federal legislatures will continue to grapple with this issue, and even more so
with ovarian tissue transplants.
In 2007, the FDA enacted eligibility regulations for Donors of Human
Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps).9 Gamete
donations were explicitly included as covered HCT/Ps under the regulation.10
As a result, oocyte and sperm donations are now regulated under 21 C.F.R. §
1271.3(d).11 If the FDA explicitly includes ovarian tissues as HCT/Ps under
their cell and tissue regulation, OTC will be regulated similarly to egg
donation procedures. However, the FDA’s guidance does little to regulate
access or availability to procedures that use HCT/Ps, which are the ARTs

4
Although scientific literature has historically used the term “women” to refer to cisgender females,
these processes may impact a larger group of individuals than the term suggests.
5
Maya Sabatello, Regulating Gamete Donation in the U.S.: Ethical, Legal and Social Implications,
4 LAWS 352, 353 (2015).
6
Sabatello, supra note 5. Generally, somatic cells are all the cells of the body except for the germ
line, consisting of gametes. Shawn Burgess, Somatic Cells, NAT’L H UM. GENOME RSCH. INST.,
https://www.genome.gov/genetics-glossary/Somatic-Cells (last visited Nov. 2, 2021). Gametes are the
cells in sexual organs that produce sperm and eggs. Id. Thus, any cell that is not involved in the production
of sperm or eggs is a somatic cell. Id.
7
Sabatello, supra note 5.
8
Chloe Nelson, No Payment, No Procreative Liberty: The Case Against Restrictions and
Prohibitions on Payment for Gametes 11 (Seton Hall Univ., Law School Student Scholarship No. 1179,
2021), https://scholarship.shu.edu/cgi/viewcontent.cgi?article=2180&context=student_scholarship.
9
Sabatello, supra note 5.
10
Id.
11
21 C.F.R. § 1271.3(d) (2020).
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themselves. Instead, its guidance merely imposes safety and administrative
guidelines for health institutions performing HCT/P procedures.12
Under C.F.R. Part 1271, Subpart C, medical clinics are required to screen
and test cell and tissue donors to prevent the introduction, transmission, or
spread of communicable diseases.13 Nonetheless, there are exceptions. Most
reproductive gamete donations qualify for an exception under the testing and
screening requirements because they are (1) cells being placed back into the
patient from which they were first harvested, (2) reproductive cells or tissues
donated by a sexually intimate partner, or (3) cryopreserved material not
previously tested.14 The third exception addresses situations where the donor
of cryopreserved reproductive cells or tissues has subsequently become
infertile.15 In this category, the FDA distinguishes between cryopreserved
cells/tissues and cryopreserved embryos.16 However, there is no mention of
cryopreservation outside of the reproductive context.17
There are three reasons the FDA, rather than HHS, should regulate OTC.
First, the OTC procedure can ultimately lead to pregnancy, which arguably
ties it to a “basic human right: the right to or not to reproduce.”18 As the
social sphere surrounding reproductive access and autonomy can be
contentious and politically charged, HHS may be reluctant to include ovarian
tissue in its organ donation regulations.19
Second, ovarian tissue does not have to be stimulated prior to
cryopreservation,20 making it a viable option for patients who cannot defer
fertility treatment. In these cases, it would be unreasonable to require
recipients to register under the Organ Procurement and Transplantation

12
Among other things, Title 21 of the Code of Federal Regulations, Part 1271, instructs clinics on
HCT/P registration, donor eligibility requirements, current good tissue practice requirements, and
reporting and labeling requirements. See id. § 1271.1(b) (describing the scope of the regulation).
13
Id. § 1271.45(b).
14
Id. § 1271.90(a)(1)–(3).
15
Id. § 1271.90(a)(3)(i).
16
Id. § 1271.90(a)(3)–(4).
17
Id. § 1271.90(a)(4)(b).
18
Lisa Campo-Engelstein, Gametes or Organs? How Should We Legally Classify Ovaries Used for
Transplantation in the USA?, 37 J. MED. ETHICS 166, 169 (2011).
19
See id. at 168 (“[T]hat reproductive healthcare continues to remain marginalised, in part because
it is so politically charged, may make the government and UNOS reluctant to include [OTC].”) (footnotes
omitted). The United Network for Organ Sharing (UNOS), which regulates organ donations, is under
contract with HHS. UNOS Wins Contract to Continue as National Transplant Network, UNITED
NETWORK FOR ORGAN SHARING (Nov. 7, 2018), https://unos.org/news/unos-wins-contract-to-continueas-national-transplant-network/.
20
Camille Ladanyi et al., Recent Advances in the Field of Ovarian Tissue Cryopreservation and
Opportunities for Research, 34 J. ASSISTED REPROD. & GENETICS 709, 711 (2017).
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Network waitlist, which HHS requires for organ transplant patients,21 due to
the often time-sensitive nature of OTC’s use.
Third, and significantly, in the context of gamete and embryo donation,
donors, recipients, and fertility programs “have a unique and ongoing moral
relationship” with one another.22 Organ donations under HHS are heavily
regulated.23 If ovarian tissue donations are similarly regulated, reproductive
liberties could potentially be encroached upon.24 Such regulation has the
potential to open a “Pandora’s box” of even more government intrusion into
the hypothetical right to, or not to, reproduce.25 Any legislative or
administrative framework also risks restricting access to those who conform
to the heteronormative family ideal.26
Some scientists view stem cells as having the potential to play a vital role
in future infertility treatments.27 Thus, if OTC is regulated by the FDA, the
FDA’s regulation of stem cell cryopreservation may foreshadow the treatment
of ovarian tissue. For stem cell donors, testing and screening requirements still
apply.28 However, it can hardly be said that ovarian tissue is better analogized
to stem cells than reproductive cells. Stem cells can indefinitely divide to
produce new cells and can change into other types of cells.29 The sole function
of ovarian tissue, which does not have these capabilities, is to aid in oocyte
production and reproductive hormone regulation.30 However, the uncertainty
in these distinctions could leave a gap in the legislative framework covering
OTC, where ART regulation is already insufficient.
21

42 C.F.R. § 121.2 (2021) (defining “transplant candidate” as someone who would benefit
medically from a transplant “and has been placed on the waiting list”); see also id. § 121.5(b) (2021)
(requiring transplant programs to place candidates on the waiting list).
22
Ethics Comm. of the Am. Soc’y for Reprod. Med., Interests, Obligations, and Rights in Gamete
and Embryo Donation: An Ethics Committee Opinion, 111 FERTILITY & STERILITY 664, 664–65 (2019).
23
About Us, HEALTH RES. & SERVS. ADMIN.: ORGANDONOR.GOV (Oct. 2021),
https://www.organdonor.gov/about-us (“Organ and tissue donation and transplantation are among the
most regulated areas in health care.”).
24
Campo-Engelstein, supra note 18, at 168.
25
See generally Angeline Faye Schrater, Pandora’s Box: Feminism Confronts Reproductive
Technology, 5 REPROD. HEALTH MATTERS 187, 189 (1997) (reviewing NANCY LUBLIN, PANDORA’S
BOX: FEMINISM CONFRONTS REPRODUCTIVE TECHNOLOGY (1998)) (noting that “[w]hen the government
and/or the medical profession view the fetus as a separate person, pregnant women lose personal
autonomy and are considered either incompetent or the enemy of the fetus”).
26
Jill Allison, Enduring Politics: The Culture of Obstacles in Legislating for Assisted Reproduction
Technologies in Ireland, 3 REPROD. BIOMED. & SOC’Y ONLINE 134, 136 (2016).
27
Jing Wang et al., Stem Cells as a Resource for Treatment of Infertility-Related Diseases, 19
CURRENT MOLECULAR MED. 539, 540 (2019).
28
How Are Stem Cells Regulated?, ASS’N FOR THE ADVANCEMENT OF BLOOD & BIOTHERAPIES,
https://www.aabb.org/news-resources/resources/cellular-therapies/facts-about-cellular-therapies/how-arestem-cells-regulated (last visited Nov. 24, 2021).
29
Yvette Brazier, What Are Stem Cells, and What Do They Do?, MED. NEWS TODAY (Oct. 19,
2018), https://www.medicalnewstoday.com/articles/323343#sources.
30
Evaluating Ovarian Function, PACIFIC FERTILITY CTR., https://www.pacificfertilitycenter.com/
infertility-diagnosis/evaluating-ovarian-function (last visited Nov. 24, 2021).
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II. INSURANCE COVERAGE IMPLICATIONS
In addition to legislation, ARTs are indirectly regulated through insurance
coverage classifications.31 Despite the increasing usage of fertility treatments,
only twenty-five percent of employers provide insurance coverage for
ARTs.32 Moreover, women with a lower socioeconomic status are less likely
to have insurance plans that cover or offer to cover ARTs.33 Neither Medicare
nor Medicaid provides insurance coverage for infertility or in vitro
fertilization (IVF).34 Private insurances occasionally include IVF coverage in
their plans, but some exclude the hormonal IVF stimulation medication
itself.35 Unfortunately, under this framework, it is improbable that OTC would
fall under ART coverage because neither eggs nor sperm are used.
Nevertheless, for the reasons stated above, OTC should fall under the
definition of ARTs for insurance purposes, especially if regulated by the FDA.
Even in states that do provide comprehensive coverage for ARTs, there
is an additional hurdle of overcoming the definition of “infertility.”36
Infertility, which affects approximately 6.1 million Americans, is defined as
“a disease of the reproductive system that impairs the body’s ability to
perform the basic function of reproduction.”37 Here, when used prior to a
gonadotoxic treatment, OTC could be used proactively to preserve one’s
fertility for later use, thus falling out of the definition. This problem is not
unique to OTC, as women who proactively freeze their eggs prior to any
additional fertility treatment are also exposed to this same pitfall. Where IVF
31

Jessica L. Hawkins, Note, Separating Fact from Fiction: Mandated Insurance Coverage of
Infertility Treatments, 23 WASH. U. J.L. & POL’Y 203, 224 (2007).
32
Id. at 204. In some states, employers are not obliged to provide insurance coverage for fertility
treatments to employees, even when coverage options are available to the employer. See, e.g., Yeager v.
Blue Cross of Cal., 96 Cal. Rptr. 3d 723, 728 (Cal. Ct. App. 2009) (contrasting home healthcare insurance
coverage requirements with the lack of legislative mandate regarding infertility coverage).
33
Madeline Curtis, Note, Inconceivable: How Barriers to Infertility Treatment for Low-Income
Women Amount to Reproductive Oppression, 25 GEO. J. ON POVERTY L. & POL’Y 323, 335 (2018).
34
Your Employer and Your Options, RESOLVE: THE NAT’L INFERTILITY ASS’N,
https://resolve.org/learn/financial-resources-for-family-building/insurance-coverage/getting-insurancecoverage-at-work/your-employer-and-your-options (last visited Mar. 30, 2022).
35
Monica Fike, 5 Questions to Ask When You’re Considering Infertility Treatment, AETNA,
https://www.aetna.com/health-guide/5-health-care-questions-ask-infertility-treatment.html (last visited
Nov. 24, 2021).
36
Fertility and Insurance, LIVESTRONG, https://www.livestrong.org/we-can-help/fertilityservices/fertility-and-insurance (last visited Nov. 26, 2021) (“[T]here is a loophole in the definition of
infertility that can exclude cancer patients. [One] may be denied coverage because [they] do not meet the
strict criteria of the definition of infertility.”); see, e.g., Daniel Basco, Lisa Campo-Engelstein & Sarah
Rodriguez, Insuring Against Infertility: Expanding State Infertility Mandates to Include Fertility
Preservation Technology for Cancer Patients, 38 J. L. MED. & ETHICS 832, 832 (2010) (“Because of [the
ASRM’s standard medical definition of fertility], even if Melanie had lived in a state where insurance
companies were mandated to pay for services to treat infertility through [ARTs], she would not have
qualified under this mandate to access fertility preservation treatments prior to undergoing treatment for
her cancer.”).
37
Hawkins, supra note 31, at 205.
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is not covered by insurance or where there is no comprehensive coverage
offered, it is unlikely that there will be coverage for OTC. It is problematic
that the fate of OTC regulation and coverage—like infertility coverage—is
likely to be a political question rather than a clinical categorization.38 When
OTC becomes widely available for nonmedically necessary use, this will
add to the complexity of providing access to those who need OTC treatment
for medical reasons.
Due to the high costs of fertility treatment, finances, rather than medical
necessities, are the driving factor in reproductive choice and access.39 The
United States has the most expensive ARTs in the world, resulting from the
high cost of healthcare and the lack of support for ART treatments in states
without ART insurance mandates.40 Without widespread insurance coverage,
it is unlikely that more women will have access to ARTs regardless of the new
technologies that become available. The cost of egg freezing alone can fall
between $15,000 and $20,000 per cycle, depending on geographic location.41
To subsequently use frozen eggs, women traditionally need to implant
fertilized embryos through IVF, which adds approximately $11,000 to the
cost.42 While not medically necessary, it is highly recommended that patients
take medications that increase the chances of a successful transfer, which can
cost anywhere from $5,000 to $8,000 more.43 In addition, many women need
to do multiple egg freezing cycles to feel confident that the number of eggs
stored will be sufficient to lead to a successful pregnancy,44 which further
increases the cost of these procedures. In total, the entire process can take
many years and cost up to $40,000.
Even without comprehensive insurance coverage, OTC may drastically
38

Patricia Stapleton & Daniel Skinner, The Affordable Care Act and Assisted Reproductive
Technology Use, 34 POL. & LIFE SCIS. 71, 80 (2015).
39
Hawkins, supra note 31, at 204; Stapleton & Skinner, supra note 38, at 75 (“[T]he choice to
pursue ART . . . is highly influenced by income.”); see also Kinzie v. Physician’s Liab. Ins. Co., 750
P.2d 1140, 1141–42 (Okla. Civ. App. 1987) (holding that an infertile woman’s IVF procedure was not
covered by her insurance policy because it did not cure or reverse her infertile condition and therefore
was not “medically necessary” as required under the policy).
40
Georgina M. Chambers et al., The Impact of Consumer Affordability on Access to Assisted
Reproductive Technologies and Embryo Transfer Practices: An International Analysis, 101 FERTILITY
& STERILITY 191, 196 (2014) (noting that “[o]ne fresh IVF cycle accounts for 52% of an individual’s
average disposable income in states without ART insurance mandates”).
41
Jamie Grifo, Egg Freezing: The Costs of Egg Freezing, FERTILITYIQ,
https://www.fertilityiq.com/egg-freezing/the-costs-of-egg-freezing#breaking-down-the-likely-costs (last
visited Nov. 26, 2021) (including the cost of treatment, medication, and around five years of storage).
42
How Much Does It Really Cost to Freeze Eggs?, CNY FERTILITY, https://www.cnyfertility.com
/egg-freezing-cost (Oct. 12, 2020) (including monitoring, egg thawing, fertilization, and egg transfer in
the cost calculation).
43
Speaking of Psychology, Bonus Episode: Debunking Myths About Fertility with Angela Lawson,
PhD, AM. PSYCH. ASS’N (Sept. 4, 2019), https://www.apa.org/research/action/speaking-of-psychology/
fertility.
44
How Much Does It Really Cost to Freeze Eggs?, supra note 42.
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reduce the costs associated with ART treatments. Ovarian tissue removal
costs are estimated to be about $10,000, with ovarian tissue preservation
prices similar to egg preservation storage prices.45 With egg freezing, OTC
patients do not need hormonal stimulation medication before the retrieval
process, and multiple retrieval cycles are presumably not needed.46 Although
there are costs associated with the transplant component of OTC,47 it is
unlikely that this cost will compare to that of IVF.
Most newly diagnosed cancer patients, like those who are currently
eligible for OTC, do not meet the definition of infertility.48 The critical
distinction between OTC and other ARTs is that fertility in OTC recipients
can come and go, while most ART treatments are used when fertility is no
longer at play. In cases where gonadotoxic treatment, such as cancer
treatment, eliminates a woman’s fertility, a subsequent ovarian tissue
transplant can stimulate follicle growth and revive it. This unique feature
may lead insurance companies to offer some coverage for the transplant
procedure but not for the retrieval and storage costs. For adults faced with
this decision, patients may be forced to choose between delaying treatment,
in order to fit the infertility definition and afford the first part of the OTC
process, and receiving treatment, which comes with its own set of additional
costs. Although patients can later pursue insurance appeals for procedure
costs, patients may be unaware of the appeals process or these processes may
simply be too complex to navigate.49
III. CONCERNS FOR FUTURE ELECTIVE OTC USE
In 2014, the ASRM noted that OTC should not be offered for the sole
purpose of delaying childbearing, outside of a nonessential context, due to
the procedure’s experimental nature.50 It remains to be seen whether the
ASRM will now draw a distinction between elective cryopreservation for
eggs and elective cryopreservation for ovarian tissue.
Although increasing access to fertility-preserving techniques is, and
should be, encouraged, specific concerns arise in the context of elective ART
45

Fertility Preservation Options for Women, LIVESTRONG, https://www.livestrong.org/we-canhelp/fertility-services/fertility-preservation-options-women (last visited Nov. 26, 2021).
46
See Rowell et al., supra note 3 (noting that the surgical procedure itself includes “thinning the
ovarian tissue while removing the medullary region . . . and preserving the cortical region”).
47 See Mindy Christianson, Ovarian Tissue Freezing (Cryopreservation), JOHNS HOPKINS MED.,
https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/ovarian-tissue-freezingcryopreservation (last visited Nov. 26, 2021) (stating that “[t]here is a charge for the tissue-harvesting
procedure, freezing and storage, as well as for the transplantation procedure when the person wishes to
become pregnant”).
48
Fertility and Insurance, supra note 36.
49
Id.
50
The Prac. Comm. of the Am. Soc’y for Reprod. Med., Ovarian Tissue Cryopreservation: A
Committee Opinion, 101 FERTILITY & STERILITY 1237, 1240 (2014).
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procedures. It is unclear whether courts would recognize a positive right to
the financial assistance needed to become a parent,51 but, generally, they
have not recognized a blanket right to reproduce.52 As a result, some believe
that “rich people reproduce better than poor people.”53 In the United States,
as of 2010, non-Hispanic white women were approximately twice as likely
as both Hispanic women and non-Hispanic Black women to have used
ARTs.54 Even in states that provide comprehensive insurance coverage for
ARTs, most of the individuals who access those services are white, highly
educated, and high-income earning women.55 Women of color bear
disproportionate financial and emotional burdens associated with infertility
treatment.56 As Hispanic and Black women are more likely to experience
infertility than white women,57 this discrepancy highlights how access to
reproductive technologies falls short for certain marginalized groups of
women. Without comprehensive insurance coverage, it is extremely unlikely
that the reduced out-of-pocket costs of OTC will help break down existing
barriers to reproductive technology access.
Putting costs aside, the largest difference between the ovarian tissue
harvesting in OTC and the egg retrieval process in egg freezing is time.
Unlike with egg harvesting, which involves rounds of hormone therapy
before retrieval and a post-operation recovery, ovarian tissue retrieval only
has a post-operation recovery period.58 With doctors recommending multiple
rounds of egg stimulation and retrieval, the egg retrieval process can take
nearly nine months.59 Egg retrieval also requires a hormonal stimulation

51

Curtis, supra note 33, at 341.
See J.B. v. M.B., 783 A.2d 707, 717 (N.J. 2001) (allowing pre-embryos to be terminated against
an ex-husband’s wishes, noting that the ex-wife’s “fundamental right not to procreate is irrevocably
extinguished if a surrogate mother bears” the ex-husband’s child).
53
Claudia Geib, Advanced Reproductive Technology Is Here. But Who Decides Who Gets Access?,
FUTURISM (Feb. 2, 2018), https://futurism.com/gatekeepers-future-reproductive-technology.
54
Molly Quinn & Victor Fujimoto, Racial and Ethnic Disparities in Assisted Reproductive Technology
Access and Outcomes, 105 FERTILITY & STERILITY 1119, 1120 (2016) (finding that “during 2006-2010 ever
using medical help to achieve pregnancy was more significantly more common among non-Hispanic white
women (15%) than among Hispanic (7.6%) or non-Hispanic [B]lack (8.0%) women”).
55
Stapleton & Skinner, supra note 38, at 75.
56
Isabel Galic et al., Disparities in Access to Fertility Care: Who’s In and Who’s Out, 2 F&S REPS.
109, 116 (2021); Usha Lee McFarling, For Black Women, the Isolation of Infertility is Compounded by
Barriers to Treatment, STAT (Oct. 14, 2020), https://www.statnews.com/2020/10/14/for-black-womenisolation-of-infertility-compounded-by-barriers-to-treatment/ (noting that studies suggest that although
Black women may be twice as likely as white women to struggle with infertility, they are half as likely
to seek or receive infertility treatment).
57
Curtis, supra note 33, at 329.
58
OTC has an approximate five-day recovery period post-operation, similar to a tubal ligation
procedure. Infertility Ctr. of St. Louis, Ovarian Tissue Freezing for Healthy Women, YOUTUBE, at 03:06
(Sept. 21, 2015), https://www.youtube.com/watch?v=UgWFz3NcoMQ.
59
Id. at 02:25.
52
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period, which is accompanied by regular doctors’ visits and tests. These
hormonal changes often come with emotionally and physically taxing stress
and mood changes.61 Routine visits and tests, in conjunction with other side
effects, may also force patients to take time off from work or put aside career
goals. Hence, ovarian tissue harvesting has far fewer side effects than IVF
egg hormonal stimulation.
The “convenience” of the OTC procedure will likely be attractive to
some working women due to its cost and efficiency. However, OTC
“[a]vailability is not synonymous with equity.”62 Working women who can
elect whether they want to preserve their ovarian tissue will likely pursue
OTC to delay childbearing as they age. This is consistent with the trend seen
in the age gap of first-time mothers. On average, women with college
degrees become mothers at age thirty, whereas women without college
degrees become mothers at around age twenty-three.63 It has been said that
women with higher socioeconomic statuses “just have more potential things
they could do instead of being a parent, like going to college or grad school
and having a fulfilling career.”64 For those women (or families) who can
afford egg freezing, ARTs can be viewed as a tool to advance career
interests.65 Some view giving birth and raising children as taking time,
energy, and resources away from a woman’s career and putting them into
her family life.66 Consequently, it is often viewed as implausible for a
woman to concomitantly succeed in her career and become a
mother.67 Elective egg freezing is arguably a way for wealthy people to “get
a leg up over those . . . who aren’t.”68 This aligns with the ideology that
fertility preservation is a solution to the “speed bump” that motherhood puts
on women’s careers.69 However, this perception is not only damaging to
60
Your Egg Freezing Cycle, EXTEND FERTILITY, https://extendfertility.com/services/egg-freezing/
your-egg-freezing-cycle (last visited Jan. 12, 2022).
61
What to Expect from Ovarian Stimulation in IVF, ASPIRE FERTILITY: ASPIRE BLOG (Nov. 29,
2015), https://www.aspirefertility.com/blog/what-to-expect-from-ovarian-stimulation-in-ivf.
62
Allison, supra note 26, at 135.
63
Quoctrung Bui & Claire Cain Miller, The Age that Women Have Babies: How a Gap Divides
America, N.Y. TIMES: UPSHOT (Aug. 4, 2018) https://www.nytimes.com/interactive/2018/08/04/upshot
/up-birth-age-gap.html.
64
Id. (“Heather Rackin, a sociologist at Louisiana State University who studies fertility”).
65
Erin Gloria Ryan, Hot New Having It All Tip: Just Be Rich Enough to Freeze Your Eggs!,
JEZEBEL (Apr. 17, 2014, 1:50 PM), https://jezebel.com/hot-new-having-it-all-tip-just-be-rich-enough-tofreez-1564318500.
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women who do choose to freeze their eggs, but it also reinforces the notion
that women cannot “have it all”—both a family and a career. If OTC is viewed
as a kind of fertility insurance, just as egg freezing is for some women, we will
likely see the same reproductive access issues arise in this context.
IV. THE BIGGER PICTURE
Those struggling with infertility find that neither the Americans with
Disabilities Act nor the Pregnancy Discrimination Act provides them with
sufficient protection for the coverage of infertility treatment costs.70 The
importance of ART access coincides with concepts of motherhood and
family, which bear heavily on women struggling with infertility.71
Regardless of the cause, women endure the burden of infertility
treatment and management and the psychological and interpersonal stressors
that accompany it.72 It has been said that the issue of establishing medical
necessity for insurance coverage purposes is a broader normative question
of the extent to which society prioritizes fertility.73 The same could be said
for the definition of infertility. Through certain customs, institutions, and
norms, society reinforces the notion that bearing and rearing children are
central to a woman’s worth.
Nearly ten percent of those needing gonadotoxic treatment are still in
their childbearing years.74 Proponents of OTC treatment pronounce that the
remarkability of the treatment is that it allows young cancer patients to
preserve their fertility.75 This exposes an underlying message—that beating
cancer is not enough. It suggests that young women need to beat cancer so
that they can become biological mothers. This becomes inherently
problematic when social perceptions of motherhood are reinforced from a
young age. Some women have already decided that they want to become
mothers before receiving a cancer diagnosis. But, for prepubescent girls, this
70
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issue would presumably have to be addressed, and, frankly, decided, at a
very young age. This perpetuates the idea that the only way for a woman to
fulfill her purpose is to become a mother, ensuring that same-sex mothers,
late-in-life mothers, infertile women, and other nondominant family
structures are considered out of the norm.76
The Edinburgh criteria,77 used in examining ideal OTC candidates, also
suggest that social norms regarding age and infertility are at play here. By
framing the “ideal” candidate in terms of age, the criteria implement yet
another barrier for women to overcome in receiving infertility treatment. On
the one hand, it is undeniable that there is a medical “tipping point” in
women’s fertility after age thirty-five,78 when egg quality and quantity
decrease more noticeably.79 On the other hand, it is entirely possible for
women to get pregnant after age thirty-five.80 There is a debate about using
thirty-five as a “cutoff” age for fertility, as a Society for Assisted
Reproductive Technology (SART) study showed that ART success rates
greatly decrease beyond age forty.81
Even outside of the fertility context, there is the argument that older
women might not have the energy and patience to raise children as they
76
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continue to age.82 The mandate of motherhood theory traditionally requires
that a woman can only become educated, work, and have a public life as long
as she first has children and raises them “well.”83 But this is in sharp contrast
to the view that older women make better mothers, as they tend to have more
stable relationships, higher levels of education, and financial stability.84 In
each contrasting position, however, the common ideology lies in the fact that
a woman’s social value is closely tied to her reproductive capabilities and her
fated motherhood. In addition to social perceptions of age and motherhood,
issues surrounding access to reproductive care, corporate culture, lack of paid
paternal leave for new parents, perceptions of motherhood for racial minority
women, and lack of affordable childcare underlie each of these arguments.
CONCLUSION
The combination of the high treatment costs, lack of widespread
insurance coverage for ARTs, and social norms make it almost impossible
for women with a lower socioeconomic status or those who come from
traditionally marginalized groups to collectively overcome existing barriers
of access to fertility treatments.85 The social forces illustrated in this context,
such as reproductive justice and socioeconomic status, are not unique to
OTC. The same dichotomy between increasing availability and increasing
access generally exists in reproductive regulation and ARTs.
More regulatory framework is needed for reproductive technologies.
Due to the strong link between social identity and reproduction, regulation
of OTC will have real-world consequences. Although the advancement of
OTC should be celebrated for its ability to provide women a way to preserve
their fertility on short notice, there are concerns similar to those in the
context of egg freezing when looking at this procedure for elective use.
These concerns illuminate the ways in which current insurance and
regulatory schemes fall flat in providing meaningful coverage to those who
need it most and illustrate how reproductive justice and cultural norms
impact ART advancements.
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